Sol-Gel Technologies (SLGL) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Upstream Bio (UPB) over the past year, gaining 78.9% versus a loss of 76.0%. Upstream Bio is the larger company by market cap ($251.4 million vs $233.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | UPB |
|---|---|---|
| Share price | $71.19 | $4.59 |
| Market cap | $233.08M | $251.40M |
| 1-day change | +1.21% | +0.88% |
| YTD return | +66.92% | -83.24% |
| 1-year return | +78.89% | -75.95% |
| 5-year return | -24.57% | — |
| EPS (TTM) | $-5.61 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $33.68 |
| 52-week low | $28.81 | $4.37 |
| Distance from 52-week high | -27.33% | -86.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +114.22% | +578.43% |
| Average volume | 55.55K | 647.42K |
| Shares outstanding | 3.27M | 54.77M |
| Employees | 28 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed UPB by 154.8 percentage points over the past year.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
SLGL vs UPB FAQ
Which is bigger, Sol-Gel Technologies or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $251.40M compared with $233.08M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, SLGL or UPB?
SLGL returned +78.89% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.